[1] BRESNAHAN E, LINDBLAD K E, RUIZ DE GALARRETA M, et al. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma[J]. Clin Cancer Res,2020,26(20):5276-5286. [2] SUNG H, FERLAY J, SIEGEL R L, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin,2021,71(3):209-249. [3] GOYAL L, ZHENG H, ABRAMS T A, et al.A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma[J]. Clin Cancer Res,2019,25(1):80-89. [4] GUAN L, WU W, PANG H, et al.Anti-GPC3 single-chain scFv antibody acts as an agent for radio-immunoimaging in diagnosing hepatocellular carcinoma[J]. Am J Transl Res,2019,11(12):7422-7431. [5] KWON S, YANG W, MOON D, et al.Comparison of Cancer Cell Elasticity by Cell Type[J]. J Cancer,2020,11(18):5403-5412. [6] XU Q, LI Y, GAO X, et al.HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer[J]. Nat Commun,2020,11(1):3978. [7] YAU T, KANG Y K, KIM T Y, et al.Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial[J]. JAMA Oncol,2020,6(11):e204564. [8] CHEN Q, LI F, GAO Y, et al.Identification of Energy Metabolism Genes for the Prediction of Survival in Hepatocellular Carcinoma[J]. Front Oncol,2020,10:1210. [9] LI Y, ZHENG X, ZHU M, et al.MoIVD-Mediated Leucine Catabolism Is Required for Vegetative Growth, Conidiation and Full Virulence of the Rice Blast Fungus Magnaporthe oryzae[J]. Front Microbiol,2019,10:444. [10] JIANG Z, WEI Z, CHEN J, et al.BZW2, CDT1 and IVD Act As Biomarkers for Predicting Hepatocellular Carcinoma[J]. Curr Cancer Drug Targets,2023,23(3):211-221. [11] KHAN A, ZAHID B, KHAN S, et al.Isovaleric Acidemia: A Rare Case of an Inborn Error of Metabolism[J]. Cureus,2020,12(2):e7150. [12] SHARMA D, SINGH M, RANI R.Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics[J]. Semin Cancer Biol,2022,87:184-195. [13] GUO Y, LI X, SUN X, et al.Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine[J]. Int J Biol Sci,2019,15(9):1771-1786. [14] TU K, LI J, MO H, et al.Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma[J]. Int J Med Sci,2021,18(9):2030-2041. [15] GUO B, XU X, SHAO M, et al.UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response[J]. Biochem Biophys Res Commun,2022,613:207-213. [16] FAN J, DU W, KIM-MULLER J Y, et al. Cyb5r3 links FoxO1-dependent mitochondrial dysfunction with β-cell failure[J]. Mol Metab,2020,34:97-111. [17] ZHAO Y, ZHANG J, WANG S, et al.Identification and Validation of a Nine-Gene Amino Acid Metabolism-Related Risk Signature in HCC[J].Front Cell Dev Biol,2021,9:731790. [18] ZHANG K, CHEN D, MA K, et al.NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer[J]. J Med Chem,2018,61(16):6983-7003. [19] LIN L, SUN J, TAN Y, et al.Prognostic implication of NQO1 overexpression in hepatocellular carcinoma[J]. Hum Pathol,2017,69:31-37. [20] HATO T, GOYAL L, GRETEN T F, et al.Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions[J]. Hepatology,2014,60(5):1776-1782. |